Evidence map›Paper›PMID 39114975›Full record

ArticleHead & neck2025

A novel prognostic score (HAMP) for head and neck cancer patients with single and multiple SBRT-treated lung metastases derived from retrospective analyses of survival outcome.

Samuel M Vorbach, Thomas Seppi, Manuel P Sarcletti, Siegfried Kollotzek, Julian Mangesius, Jens Lehmann, David Riedl, Martin J Pointner, Matthias Santer, Daniel Dejaco and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Samuel M VorbachDepartment of Radiation Oncology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0009-0003-1711-1604
Thomas SeppiDepartment of Radiation Oncology, Medical University of Innsbruck, Innsbruck, Austria.
Manuel P SarclettiDepartment of Radiation Oncology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0009-0002-5468-2855
Siegfried KollotzekDepartment of Radiation Oncology, Medical University of Innsbruck, Innsbruck, Austria.
Julian MangesiusDepartment of Radiation Oncology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0003-0855-1870
Jens LehmannDepartment of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, University Hospital of Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria.
David RiedlDepartment of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, University Hospital of Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria.
Martin J PointnerDepartment of Radiation Oncology, Medical University of Innsbruck, Innsbruck, Austria.
Matthias SanterDepartment of Otorhinolaryngology - Head and Neck Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Daniel DejacoDepartment of Otorhinolaryngology - Head and Neck Surgery, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0001-9176-7415
Meinhard Nevinny-StickelDepartment of Radiation Oncology, Medical University of Innsbruck, Innsbruck, Austria.
Ute GanswindtDepartment of Radiation Oncology, Medical University of Innsbruck, Innsbruck, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe report on the characterization and introduction of a novel prognostic score for patients undergoing stereotactic body radiotherapy (SBRT) for the treatment of single and multiple pulmonary metastases (PMs) derived from head and neck cancer (HNC).

methodsIn this retrospective study, we examined selected factors associated with progression-free survival (PFS) and overall survival (OS) among 59 patients with HNC treated with SBRT for a total of 118 PMs, between 2009 and 2023. Factors related to survival were included in the prognostic scoring system.

resultsPrognostic factors including histology, age, number of metastases, and performance status at first SBRT were weighted differently depending on the strength of correlation to PFS and OS. Total prognostic scores (HAMP) ranged from 13 to 24 points, with a cut-off total score of ≤18 scoring points for patients in a high-risk (HR) subcohort, and of ≥19 scoring points for patients in a low-risk group (LR). Median PFS (23.8 vs. 5.5 months, p < 0.001) and OS (61.3 vs. 16.4 months, p < 0.001) were significantly longer in the low-risk group compared to the high-risk group.

conclusionThe HAMP score might be a convenient tool to facilitate individualized treatment decisions and appropriate follow-up. The accuracy and reliability of the score requires further evaluation in prospective studies.

Indexed as

Head and Neck NeoplasmsLung NeoplasmsRadiosurgeryAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective StudiesSurvival Analysishead and neck cancerprognostic toolpulmonary oligometastasesradiation oncologystereotactic body radiotherapy

Identifiers

PMID39114975
PMCPMC11635751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.